enGene Therapeutics (ENGN) Total Current Liabilities (2022 - 2026)
enGene Therapeutics (ENGN) posted quarterly Total Current Liabilities of $21.5 million for Q2 2026, up 19.35% year-over-year from $18.0 million in Q2 2025, and down 12.69% quarter-over-quarter from $24.6 million in Q1 2026.
enGene Therapeutics (ENGN) Total Current Liabilities (2022 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Total Current Liabilities for 5 consecutive years, with $21.5 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Total Current Liabilities rose 19.35% year-over-year to $21.5 million; the TTM figure through Apr 2026 stood at $21.5 million (up 19.35% YoY), while the FY2025 annual figure was $32.0 million, up 118.12% from the prior year.
- Total Current Liabilities declined to $21.5 million in Q2 2026 per ENGN's latest filing, from $24.6 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $32.0 million in Q4 2025 and bottomed at $5.1 million in Q4 2022.
- Historically, Total Current Liabilities has averaged $15.1 million across 5 years, with a median of $14.1 million in 2024.
- Annual changes were most pronounced in 2023 — Total Current Liabilities gained 3.0% — and 2025, when it soared 185.78%.
- enGene Therapeutics' Total Current Liabilities stood at $5.1 million in 2022, then advanced by 3.0% to $5.3 million in 2023, then surged by 178.89% to $14.7 million in 2024, then soared by 118.12% to $32.0 million in 2025, then sank by 32.82% to $21.5 million in 2026.
- Business Quant data shows ENGN's Total Current Liabilities at $21.5 million in Q2 2026, $24.6 million in Q1 2026, and $32.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - | 21.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 21.49 Mn |
| Jan 31, 2026 | 24.61 Mn |
| Oct 31, 2025 | 31.98 Mn |
| Jul 31, 2025 | 20.44 Mn |
| Apr 30, 2025 | 18.00 Mn |
| Jan 31, 2025 | 12.96 Mn |
| Oct 31, 2024 | 14.66 Mn |
| Jul 31, 2024 | 13.46 Mn |
| Apr 30, 2024 | 6.30 Mn |
| Jan 31, 2024 | 6.91 Mn |
| Oct 31, 2023 | 5.26 Mn |
| Oct 31, 2022 | 5.10 Mn |